This study is to compare pharmacokinetics and safety profiles of single-administration of DA-5222 and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects in fed state
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
single dose administration (DA-5222 one tablet once a day)
single dose administration (DA-5222-R1 one tablet once a day)
single dose administration (DA-5222-R2 one tablet once a day)
Bumin Hospital
Seoul, Gangseo-gu, South Korea
AUCt
Area Under the Curve
Time frame: pre-dose~48 hours post-dose
Cmax
Maximum Plasma Concentration
Time frame: pre-dose~48 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
single dose administration (DA-5222-R3 one tablet once a day)